IDH1 and central nervous system cancer: Due to these survival benefits, IDH1/2 mutations are not only valuable prognostic biomarkers but are also being investigated as potential therapeutic targets, with IDH inhibitors currently in clinical trials aiming to improve survival for this subset of glioma patients [50].